Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia

NCT00436904 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Alemtuzumab
DRUG: Rituximab

Sponsor

Mayo Clinic

Collaborators

[object Object]